Pfizer’s Pegfilgrastim Biosimilar ‘Has Launched’ In The US

FDA Approval In June 2020 Hung Up By IP Barriers

 
• By Dean Rudge
  
F1
Pfizer has entered the race for market share in the mult-billion-dollar US pegfilgrastim market • Source: Shutterstock

More from Biosimilars

More from Products